Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis

Priscilla P. Oomen1, Marieke J. H. Begemann1, Bodyl A. Brand1 (shared second), Lieuwe de Haan2, Wim Veling3, Sanne Koops1, Jim van Os4,5,6, Filip Smit7,8,9, P. Roberto Bakker5,10, Nico van Beveren11,12,13, Nynke Boonstra14,15, Sinan Gülöksüz5,16, Martijn Kikkert10, Joran Lokkerbo19, Machteld Marcelis17,18, Bram-Sieben Rosema1, Franciska de Beer1, Shiral S. Gangadin1, Chris N. W. Geraets3, Erna van ‘t Hag3, Yudith Haveman1, Inge van der Heijden3,19, Alban E. Voppel1, Elske Willems1, Therese van Amelsvoort1,20, Maike van den Bosch21, Truus van den Brink22, Gunnar Faber23, Koen P. Grootens24, Martin de Jonge25, Rikus Knegtering3,26, Jörg Kurkamp27, Amrita Mahabir28, Gerda H. M. Pijnenborg29,30, Tonnie Staring31, Natalie Veen32, Selene Veerman33, Sybren Wiersma34, Ellen Graveland23, Joelle Hoornaar11 and Iris E. C. Sommer1

Abstract

Background. Cognitive deficits may be characteristic for only a subgroup of first-episode psychosis (FEP) and the link with clinical and functional outcomes is less profound than previously thought. This study aimed to identify cognitive subgroups in a large sample of FEP using a clustering approach with healthy controls as a reference group, subsequently linking cognitive subgroups to clinical and functional outcomes.

Methods. 204 FEP patients were included. Hierarchical cluster analysis was performed using baseline brief assessment of cognition in schizophrenia (BACS). Cognitive subgroups were compared to 40 controls and linked to longitudinal clinical and functional outcomes (PANSS, GAF; self-reported WHODAS 2.0) up to 12-month follow-up.

Results. Three distinct cognitive clusters emerged: relative to controls, we found one cluster with preserved cognition (n = 76), one moderately impaired cluster (n = 74) and one severely impaired cluster (n = 54). Patients with severely impaired cognition had more severe clinical symptoms at baseline, 6- and 12-month follow-up as compared to patients with preserved cognition. General functioning (GAF) in the severely impaired cluster was significantly lower than in those with preserved cognition at baseline and showed trend-level effects at 6- and 12-month follow-up. No significant differences in self-reported functional outcome (WHODAS 2.0) were present.

Conclusions. Current results demonstrate the existence of three distinct cognitive subgroups, corresponding with clinical outcome at baseline, 6- and 12-month follow-up. Importantly, the cognitively preserved subgroup was larger than the severely impaired group. Early identification of discrete cognitive profiles can offer valuable information about the clinical outcome but may not be relevant in predicting self-reported functional outcomes.

Introduction

Despite relatively successful treatment of clinical symptoms after first-episode psychosis (FEP) (Kahn et al. 2018), many patients continue to experience ongoing functional impairment in day-to-day life (Henry et al. 2010; Lally et al. 2017). Large variability exists in the outcome of FEP with recovery rates ranging from 13.5% to 38% (Jääskeläinen et al. 2013; Lally et al. 2017). A significant minority of patients shows the excellent recovery, but a large proportion of patients continues to exhibit moderate or severe functional impairment (Jääskeläinen et al. 2013; Lally et al. 2017). Recovery rates appear to be stable 2 years after illness onset as demonstrated in a large meta-analysis (Lally et al. 2017), underscoring the importance of identifying factors that can predict outcome overtime in the early stages of disease onset. However, most longitudinal studies have examined predictors at the diagnostic group level and do not take the high heterogeneity between individual patients with the same diagnosis into account.
ences in severity of cognitive dysfunction. Indeed, it has been shown that both functional and clinical outcomes may be related to differences in predictive value of cognitive deficits in terms of functional outcomes over time (Helldin, Mohn, Olsson, & Hjärthag, 2020; Johansson, Hjärthag, & Helldin, 2020; Lindgren, Holm, Kieseppä, & Suvisaar, 2020; Santesteban-Echarri et al., 2017). Some authors have considered cognitive dysfunction to be the core feature of schizophrenia (Heinrichs, 2005). However, recent literature shows that global cognitive deficits are not a general finding, as it is becoming increasingly apparent that several cognitive subgroups may exist within the FEP population, including a substantial subset of patients that remains cognitively intact (Carruthers, Van Rheenen, Gurvich, Sumner, & Rossell, 2019; Moritz et al., 2017; Uren, Cotton, Killackey, Saling, & Allott, 2017). Also, the predictive value of cognitive deficits in terms of functional impairment may be less pronounced as previously thought. Notably, a recent meta-analysis showed only small to medium effect sizes for the association between cognition and functional outcome, leaving a significant proportion of the variance unexplained (Halverson et al. 2019). It is plausible that variance in both functional and clinical outcomes may be related to differences in severity of cognitive dysfunction. Indeed, it has been demonstrated that cognitive performance in a “neuropsychologically normal” range does not correlate well with aspects of everyday functioning whereas more severe levels of cognitive impairment do seem to be associated with functional outcomes (Strassnig et al. 2018). This underscores the value of grouping FEP patients into subtypes along the cognitive continuum, demonstrating possible subgroups with distinct illness profiles.

An essential and relatively novel solution for determining homogeneous subgroups is a data-driven clustering approach. Defining subgroups based on baseline cognitive profile may provide crucial information regarding functional outcome and prognosis. Such information is urgently needed, as the high heterogeneity and lack of good predictors hamper clinicians in providing optimal care for individual patients. Early identification of risk factors associated with poor outcomes is highly valuable as this would aid individually tailored interventions that may positively impact the long-term outcome.

The current study includes a large sample of FEP patients who were 3–6 months in remission of their psychotic symptoms at baseline, to identify homogeneous subgroups of cognition based on a data-driven clustering approach. Factors that may influence cognitive function, such as the distraction by unusual ideas and/or hallucinations, long-term antipsychotic medication use or the level of organization, are mild, which means (consistent with international remission criteria) that they do not interfere with behavior and daily functioning. Emergent cognitive subgroups were subsequently compared to healthy controls to assess the level of cognitive (under)performance. Cognitive subgroups were then evaluated regarding clinical [Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF)] and functional [WHO Disability Assessment Scale 2.0 (WHODAS2.0)] outcome at baseline and longitudinally at 6- and 12-month follow-up. The clinician-rated GAF has been widely used in clinical and research settings and has been adopted as meaningful, however, the DSM-5 recommends a new tool for the assessment of global functioning and impairment, the WHODAS 2.0, a patient self-report assessment tool that evaluates the patient’s ability to perform activities in six domains of functioning (Gold, 2014). Based on a recent systematic review regarding cognitive subgrouping studies in schizophrenia spectrum disorders, we expected to find three distinct cognitive subtypes; a relatively intact cognitive subgroup, an intermediate cognitive subgroup and a globally impaired subgroup (Carruthers et al., 2019). We further hypothesized that emergent cognitive subtypes are characterized by differences in both clinical and functional outcomes at baseline and follow-up.

Method

Participants

Data were used from the ongoing Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment (HAMLETT) study (Begemann et al., 2020). Patients were recruited from outpatient settings in 24 healthcare centers throughout the Netherlands. Written informed consent was obtained from all participants and study procedures were performed according to the Declaration of Helsinki (64th WMA general assembly; October 2013). Ethics approval was obtained from the research and ethics committee of the University Medical Center Groningen, the Netherlands (protocol number: NL 62202.042.17, trial registration EudraCT number: 2017-002406-12). Recruitment and study procedures are described in detail by Begemann et al. (2020).

In short, the current study included data from 204 patients aged between 16 and 60 years old with the first episode of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, substance/medication-induced psychotic disorder, or those classified as Unspecified Schizophrenia Spectrum and Other Psychotic Disorders (DSM-5, or as described in the International Classification of Diseases-10). Diagnosis and duration of illness were established by their treating psychiatrist and confirmed by the Comprehensive Assessment of Symptoms and History (CASH) (Andreasen, Flaum, & Arndt, 1992). At baseline, all patients were 3–6 months in remission of their first psychotic episode and used antipsychotic medication. Symptomatic remission is defined as “sustained improvement of psychotic symptoms to the level that any remaining psychotic symptoms (such as hallucinatory experiences, unusual thought content, conceptual disorganization) are mild, which means (consistent with international remission criteria) that they do not interfere with behavior and daily functioning.”

Self-reports of current antipsychotic medication use (mg/day) were converted into a chlorpromazine equivalent (CPZE, mg/day) for each patient (Gardner, Murphy, O’Donnell, Centorrino, & Baldessarini, 2010). The highest educational level achieved (CASH) (Andreasen et al. 1992), was converted into the number of years of education (YOE; see Online Supplementary Table S1).

Moreover, 40 healthy controls were included as a reference group for cognitive functioning. Healthy controls did not have any history of psychiatric illness and were aged between 19 and 45 years (Trial registration: ABR NL50657.041.14).

Procedures

Cognitive testing

Cognitive performance was assessed at baseline using the Dutch version of the brief assessment of cognition in schizophrenia.
(BACS) (Keefe et al. 2004). The test consists of six subtests that assess different cognitive domains, including:

1. List Learning – Verbal memory
2. Digit Sequencing Task – Working memory
3. Token Motor Task – Motor speed
4. Category Instances and Controlled Oral Word Association Test – Verbal fluency
5. Symbol Coding – Attention and information processing speed
6. Tower of London – Executive function

Performances of all participants on the subtests of the BACS were standardized by creating z-scores adjusted for gender and age using the norms of Keefe et al. (2004). A composite z-score was calculated by averaging all of the six standardized primary measures from the BACS. Participants missing more than 2 cognitive sub-scores were excluded from analysis (n = 2). For participants with ≤2 missing sub-scores, scores were replaced by the corresponding population mean for that specific domain (n = 8).

Clinical outcome
Clinical symptomatology was assessed by trained central study personnel using the Positive and Negative Symptom Scale (PANSS) at baseline, 6 months and 12-month follow-up (Kay, Fiszbein, & Opler, 1987). In addition, clinical global functioning was evaluated by trained central study personnel at baseline, 6 months and 12-month follow-up using the GAF (Jones, Thornicroft, Coffey, & Dunn, 1995).

To ensure data quality, assessors are comprehensively trained and the central team of assessors have biannual meetings during which inter-rater reliability is assessed and protocol adherence is checked.

Self-reported functional outcome
Self-reported global functioning and disability were evaluated at baseline, 6 months and 12-month follow-up using the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). This questionnaire consists of 36 items covering six domains of functioning in everyday life: cognition (understanding and communicating), mobility (moving and getting around), self-care (hygiene, eating, and staying alone), getting along (interacting with other people), life activities (domestic responsibilities, leisure, work and school) and participation (joining in community activities). Participants respond to each item on a 5-point scale from 0 (No Difficulty) to 4 (Extreme Difficulty/Cannot Do). Overall scores range from 0 to 100 with higher scores indicating a greater level of self-reported disability (Üstün, 2010).

Statistical analyses
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 25 (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Healthy controls and FEP patients were compared on demographic variables such as gender, age, years of education and cognitive performance using Pearson’s χ² (categorical variables) and One-way Analysis of Variance (ANOVA, continuous variables). Subsequently, cognitive patient clusters were compared on both clinical (PANSS, GAF) and functional (WHODAS 2.0) outcomes using ANOVA for baseline comparisons and ANCOVA for comparisons at 6- and 12-month follow-up. Post hoc comparisons were conducted for all significant ANOVA and ANCOVA effects, using Bonferroni correction for multiple comparisons.

Results
Demographics
A total of 204 patients and 40 healthy controls were included at baseline. Sociodemographic and clinical characteristics are presented in Online Supplementary Table S2. The group of patients consisted of 148 males (72.5%), the healthy controls included 32 males (80.0%). Patients were significantly older (M = 27.93, S.D. = 8.90) than healthy individuals (M = 24.48, S.D. = 4.98), (p = 0.018). Patients attained fewer years of education compared to healthy controls (p = 0.006) and patients scored significantly worse on both the BACS composite and all subtests (all p < 0.001, executive functioning p = 0.047). At 6- and 12-month follow-up, the sample consisted of 145 and 132 patients respectively.

Cluster solution
Hierarchical clustering (Ward’s method) and K-means optimization using BACS composite scores for the total sample of patients resulted in three distinct cognitive clusters (Table 1). Subgroups were subsequently compared to a group of healthy controls to assess the level of cognitive (under)performance.

One cluster could be described as a relatively preserved group (n = 76). The BACS composite score was not significantly different compared to healthy controls, yet these patients scored significantly lower on attention and processing speed compared to healthy controls (p = 0.008). An intermediate or moderately impaired cognitive cluster (n = 74) displaying reduced functioning on all cognitive domains compared to healthy controls (all p < 0.001), except for executive function (p = 0.730) was observed. Lastly, the severely impaired cognitive cluster (n = 54) showed significant impairments across all domains assessed relative to the controls, with working memory and motor speed showing the

https://doi.org/10.1017/S0033291721004153 Published online by Cambridge University Press
most severe deficits (all \( p < 0.001 \)). Results are demonstrated in Figs 1 and 2.

The relatively preserved cluster was significantly older than the healthy controls (\( p = 0.011 \)), but no age differences were demonstrated between the three cognitive patient clusters. The moderately impaired cluster and severely impaired cluster had received significantly fewer years of education compared to both the healthy controls (\( p = 0.007 \) and \( p < 0.001 \), respectively) and the relatively preserved cluster (\( p = 0.004 \) and \( p < 0.001 \), respectively). Parental years of education attained showed an overall effect (\( F(3) = 3.11, p = 0.027 \)) but no significant differences between clusters. Furthermore, chlorpromazine equivalents were not significantly different between clusters (\( p = 0.107 \)).

**Clinical outcome**

Although all patients were in clinical remission at baseline, the subgroup of patients with severely impaired cognition had significantly higher symptom severity compared to the cognitively preserved subgroup, with higher scores on the PANSS total subscale (\( p < 0.001 \)), as well as the positive (\( p = 0.014 \)), negative (\( p < 0.001 \)) and general subscales (\( p = 0.014 \)). Results are demonstrated in Fig. 3.

After correcting for clinical symptoms at baseline, the patient groups with severely impaired and preserved cognitive performance showed significant differences on PANSS negative symptomatology at 6- and 12-month follow-up (\( n = 145, p = 0.017; n = 132, p = 0.018 \), respectively). Those with severely impaired and moderately impaired cognitive performance differed on the PANSS negative subscale (6 months: \( p = 0.010 \); 12 months: \( p = 0.010 \)). Thus, consistently across time points, the group with severely impaired cognition was characterized by more severe negative symptoms compared to the other clusters at baseline, 6- and 12-month follow-up.

Furthermore, the patient subgroup with severely impaired cognition had lower clinical global functioning (total GAF score, Fig. 4) compared to patients with relatively preserved cognition, at baseline (\( p = 0.001 \)), and trend-level effects were shown for 6-month follow-up (\( n = 144; p = 0.094 \)) and 12-month follow-up (\( n = 132; p = 0.052 \)), corrected for global functioning at baseline. In addition, lower clinical global functioning was shown in the subgroup with severely impaired cognition compared to the moderately impaired cluster at baseline (\( p = 0.045 \)) and 6-month follow-up (\( p = 0.047 \)).

**Functional outcome**

Self-reported global functioning and disability were evaluated by the WHODAS 2.0. Although the clusters did not significantly differ across all time points, corrected for global functioning and disability at baseline (all \( p > 0.05 \)), there was a gradual and stepwise increase in disability, with the relatively preserved cluster having lower disability scores compared to the moderately impaired and severely impaired cluster.

**Discussion**

To the best of our knowledge, this is the largest study investigating cognitive subgroups of FEP patients who all reached symptomatic remission after treatment in relation to longitudinal clinical and functional outcomes. We found three distinct cognitive subgroups in a sample of FEP, including one relatively large subgroup with preserved cognition (37.2%), one moderately impaired group (36.3%) and one severely impaired group (26.5%) as compared to healthy controls. Of note, the severely impaired group included only one-fourth of the sample. The cognitive subgroups were characterized by significant differences in clinical symptoms, with more severe clinical symptoms in the severely impaired cognitive subgroup compared to the relatively preserved cluster, at baseline (PANSS total and all subscales) and 6- and 12-month follow-up (PANSS negative subscale). In addition, evaluation of global functioning (GAF) was significantly higher in the relatively preserved cluster compared to the severely impaired cluster at baseline and showed trend-level effects at 6- and 12-month follow-up. No significant differences in self-reported measures of functional outcome (WHODAS 2.0) were found between the patient subgroups at baseline and follow-up, yet the same trend could be observed.

The current results provide support for cognitive heterogeneity in FEP, delineated by three cognitive subtypes. This is consistent with previous clustering studies reporting on three subgroups of cognition in both first episode and chronic samples of schizophrenia (Carruthers et al. 2019; Gilbert et al. 2014; Menkes, Armstrong, Blackford, Heckers, & Woodward, 2019; Sauvé, Malla, Joober, Brodeur, & Lepage, 2018; Uren et al. 2017; Wells et al. 2015). The relatively preserved subgroup did not perform worse on overall cognition compared to the healthy controls, confirming the existence of a subset of patients with relatively intact cognitive performance (Ammari et al. 2014; Carruthers et al. 2019; Menkes et al. 2019; Moritz et al. 2017; Uren et al. 2017). Although cognitive impairment has long been recognized as a core symptom of psychotic disorders, our results show that a significant proportion of patients (37.8%) perform in the same range as healthy controls. This underscores the importance of taking individual variability into account in both research and clinical practice. It should be noted that cognitive performance similar to that of healthy controls is not necessarily synonymous with cognitively unaffected. However, no differences in years of education were observed between the relatively intact subgroup and healthy controls, and no decline relative to parents’ years of education was observed, suggesting that cognitive functioning did not decline relative to a higher premorbid level (Keefe, Eesley, & Poe, 2005). We further showed that both the moderately and severely impaired subgroups had attained significantly fewer years of education compared to the relatively preserved subgroup. The moderately impaired subgroup showed global cognitive impairment compared to the healthy controls, including all subdomains except for executive function. Findings regarding the intermediate cluster show global impairments of cognitive performance rather than domain-specific deficits. This is in line with previous studies performed in both first episode and chronic schizophrenia samples, which identified an intermediate cluster with overall moderate cognitive impairment (Lewandowski, Sperry, Cohen, & Öngür, 2014; Uren et al. 2017; Van Rheenen et al. 2016). The severely impaired subgroup (25.5%) showed pronounced cognitive impairments that were not restricted to specific domains, with more severe performance deficits compared to the other cognitive subgroups. The existence of a severely impaired cognitive subgroup has been previously demonstrated (Lewandowski et al. 2014; Uren et al. 2017; Van Rheenen et al. 2016). However, the percentage of individuals showing severely impaired cognition in this study is lower than the 44% reported in a large recent systematic review (Carruthers et al. 2019). Remarkably, executive function was relatively spared across all subgroups of cognition, although previous FEP studies demonstrated...
Table 1. Mean (s.a.) baseline demographic and cognitive characteristics for FEP cognitive clusters and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>Healthy controls (n = 40)</th>
<th>Preserved cognition (n = 76)</th>
<th>Moderately impaired cognition (n = 74)</th>
<th>Severely impaired cognition (n = 54)</th>
<th>Test statistic</th>
<th>Post hoc analyses*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n (%)</td>
<td>32 (80.0%)</td>
<td>47 (61.8%)</td>
<td>60 (81.1%)</td>
<td>41 (75.9%)</td>
<td>χ² = 8.56</td>
<td>χ² = 8.56</td>
</tr>
<tr>
<td>Age</td>
<td>24.48 (4.98)</td>
<td>29.62 (10.26)</td>
<td>26.54 (7.26)</td>
<td>27.46 (8.65)</td>
<td>F = 3.70</td>
<td>p = 0.036</td>
</tr>
<tr>
<td>Years of education</td>
<td>14.95 (1.95)</td>
<td>14.75 (1.93)</td>
<td>13.42 (2.15)</td>
<td>12.84 (3.28)</td>
<td>F = 10.31</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Years of education parents</td>
<td>13.63 (2.20)</td>
<td>13.61 (2.68)</td>
<td>12.52 (3.87)</td>
<td>12.15 (3.06)</td>
<td>F = 3.11</td>
<td>p = 0.027</td>
</tr>
<tr>
<td>Chlorpromazine equivalent</td>
<td>N.A.</td>
<td>210.11 (127.24)</td>
<td>258.62 (139.43)</td>
<td>249.88 (145.86)</td>
<td>F = 2.26</td>
<td>p = 0.107</td>
</tr>
<tr>
<td>BACS, Z-score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composite score</td>
<td>0.13 (1.15)</td>
<td>−0.18 (0.53)</td>
<td>−1.59 (0.39)</td>
<td>−3.00 (0.69)</td>
<td>F = 247.51</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Verbal memory</td>
<td>0.43 (1.01)</td>
<td>0.05 (0.84)</td>
<td>−0.83 (0.91)</td>
<td>−1.57 (0.85)</td>
<td>F = 53.43</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Working memory</td>
<td>0.07 (1.05)</td>
<td>−0.13 (0.88)</td>
<td>−0.97 (0.94)</td>
<td>−2.05 (1.00)</td>
<td>F = 55.49</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Motor speed</td>
<td>−0.15 (0.96)</td>
<td>−0.01 (0.92)</td>
<td>−1.06 (1.18)</td>
<td>−2.09 (1.21)</td>
<td>F = 44.93</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Verbal fluency</td>
<td>0.11 (1.05)</td>
<td>−0.18 (1.12)</td>
<td>−1.33 (0.80)</td>
<td>−1.91 (0.73)</td>
<td>F = 56.24</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Attention &amp; Processing speed</td>
<td>−0.23 (1.19)</td>
<td>−0.80 (0.94)</td>
<td>−1.43 (0.66)</td>
<td>−1.89 (0.73)</td>
<td>F = 33.91</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Executive function</td>
<td>0.24 (0.87)</td>
<td>0.49 (0.80)</td>
<td>−0.07 (0.72)</td>
<td>−1.21 (1.61)</td>
<td>F = 30.40</td>
<td>p = 0.001</td>
</tr>
</tbody>
</table>

FEP, first-episode psychosis; BACS, brief assessment of cognition in schizophrenia; df, degrees of freedom.

*a HC significantly different from the relatively preserved cluster; b HC significantly different from the moderately impaired cluster; c HC significantly different from the severely impaired cluster; d relatively preserved cluster significantly different from moderately impaired cluster; e relatively preserved cluster significantly different from severely impaired cluster; f moderately impaired cluster significantly different from a severely impaired cluster.
reduced executive function compared to healthy controls (Kravariti et al. 2009). Attention and speed of processing showed most severe impairments across all subgroups, which is in line with previous studies performed in FEP (Kravariti et al. 2009; Leeson et al. 2010; Weinberg et al. 2016).

Our finding of more severe clinical symptoms, specifically negative symptoms in the group with severely impaired cognition is in line with previous research demonstrating an association between cognitive function and negative symptoms in both FEP (Engen et al. 2019; Reser, Allott, Killackey, Farhall, & Cotton, 2015; Uren et al. 2017) and chronic schizophrenia (Lewandowski et al. 2014; Weinberg et al. 2016; Wells et al. 2015). However, the relationship between cognitive function and negative symptoms seems complex. Severe negative symptoms such as lack of motivation or decreased effort may impact cognitive performance but similarly, cognitive impairment could affect the manifestation of negative symptoms as more preserved cognitive function may be essential for the ability to plan, initiate, motivate and carry out daily activities (Beck, Himelstein, Bredemeier, Silverstein, & Grant, 2018; Fervaha et al. 2014; Fortgang, Srihari, & Cannon, 2020; Jurado & Rosselli, 2007; Lindgren et al. 2020). More longitudinal studies are required to gain more insight into the relationship between cognitive function and negative symptoms in FEP.

In the subgroup of individuals with severely impaired cognition, we found lower objectively evaluated global functioning (GAF) when compared to the relatively preserved subgroup. These findings are substantiated by other studies suggesting that global functioning is related to cognitive cluster membership (Gilbert et al. 2014; Lewandowski et al. 2014; Uren et al. 2017; Wells et al. 2015). Moreover, studies investigating cognitive subtypes in both psychotic patients and unaffected siblings showed that patients with cognitively impaired siblings reflect a poorer course of the disease. This suggests that cognitive impairment may indeed be predictive for the course of illness (Burger et al. 2021; Quee et al. 2014). However, no significant differences between cognitive subgroups could be demonstrated on self-reported measures of functional outcome (WHODAS 2.0). This is remarkable, as both the GAF and the WHODAS 2.0 assess measures of outcome. It is plausible that not all types of cognition are associated with the evaluation of functional outcomes. It has been suggested that not global cognition but specifically social cognition plays a critical role in outcome regarding everyday functioning. A recent study by Kim et al. (2021) demonstrated significant correlations between the WHODAS 2.0 and social cognition, such as communication and learning abilities (Kim et al. 2021). Similarly, Tan, Rossell, and Lee (2020) demonstrated that mostly verbal-linguistic cognitive skills such as semantics and language are associated with subjective measures of functioning and well-being, as those have a direct effect on community functioning (Tan et al. 2020). Indeed, medium to large associations between social cognition and community functioning have been reported in a meta-analysis (Fett et al. 2011), whereas only small to moderate associations have been reported between nonsocial cognition and functional outcome (Halverson et al. 2019). This suggests that interventions targeting social cognition may improve functional

Fig. 1. BACS composite means Z-scores illustrated for FEP cognitive clusters and healthy controls. Error bars represent standard deviations. All groups showed significant differences ($p < 0.05$) except for healthy controls compared to the preserved cognitive cluster. BACS, brief assessment of cognition in schizophrenia; FEP, first-episode psychosis.
outcomes more than neurocognitive interventions. Another explanation for the lack of differences in WHODAS 2.0 between the cognitive subgroups may be the lack of awareness of functioning and disability in patients as the accuracy of assessing daily functioning in patients with schizophrenia is under debate (Jongs et al. 2020). An overestimation of functioning by the patient may be affected by disease-related factors such as negative symptomatology and lack of insight (Jongs et al. 2020; Sabbag et al. 2012). This indicates that despite symptoms or restrictions in clinician observed functioning, patients may be satisfied with their lives and consider their level of functioning high. Thus, our findings suggest that daily functioning from a patient’s perspective is not necessarily synonymous with the clinician’s interpretation of recovery and may be related to a different set of predictors. Finally, the WHODAS 2.0 includes domains of daily functioning that are hardly affected in the current FEP sample and only minimally associated with cognitive function, such as mobility (getting around, standing up, walking a long-distance) and self-care (getting dressed, washing, eating) and hence do not differentiate between the groups (Chen et al. 2018).

**Strengths, limitations and future directions**

A strength of the current study is its large sample size and longitudinal design, evaluating both clinical and functional outcomes over a 12-month follow-up period. The participants were included shortly after diagnosis and had all achieved symptomatic remission before the baseline measurement. Therefore, factors that may influence cognitive function, such as long-term antipsychotic medication use or duration of illness, are being limited. In addition to the assessment of clinical outcome (PANSS and GAF) by trained central raters, we extensively measured functioning and disability with the self-reported WHODAS 2.0 questionnaire, which is recommended for the assessment of functioning in the DSM-5 (Gold, 2014). We also note that our study comes with some limitations. First, antipsychotic medication use was not stable for all participants throughout follow-up as some participants may have tapered off their antipsychotic medication gradually. However, the process of medication discontinuation also occurs in the general population of first-episode patients. Furthermore, although we did not include a cumulative dose of antipsychotic medication as a factor, all participants were in a similar early stage of the illness (3 to 6 months in remission of their first psychotic episode) at the time of inclusion and we found that current chlorpromazine equivalents were not significantly different between clusters. Moreover, although cognitive performance at baseline was not affected by psychotic symptoms as solely patients in symptomatic remission were included, generalizability to wider FEP populations may be limited within this study. Finally, cluster analyses come with the limitation that the
Fig. 3. PANSS mean scores illustrated for FEP cognitive clusters at baseline, 6-month follow-up and 12-month follow-up comparisons at 6- and 12-month follow-up were corrected for clinical symptoms at baseline. * illustrates $p < 0.05$; Error bars represent standard deviations. PANSS, Positive and Negative Syndrome Scale; FEP, first-episode psychosis.

Fig. 4. GAF mean scores illustrated for FEP cognitive clusters at baseline, 6-month follow-up and 12-month follow-up GAF, Global Assessment of Functioning; FEP, first-episode psychosis.
Conclusion

The results of the present study provide strong support for high heterogeneity in cognition among FEP patients who reach symptomatic remission. Besides finding a moderately impaired and severely impaired subgroup, we also show that a significant subset of patients have relatively preserved cognitive function. This underscores the importance of taking individual variability into account. In addition, we found that FEP patients with severe cognitive impairment have poor clinical outcomes compared to those with relatively preserved cognitive function. These findings suggest that grouping patients in subtypes along the cognitive continuum may offer crucial information about illness profiles and clinical prognosis. In conclusion, early identification of distinct cognitive profiles in FEP and corresponding longitudinal differences in clinical profile has clear implications for prognosis and personalized treatment of psychotic disorders. However, self-reported measures of functional outcome seem to have different sets of predictors in FEP and more longitudinal studies are required to further assess determinants of functional outcome.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291721004153.

Acknowledgements. We would like to thank all of our participants, collaborators and dedicated includers who assist in recruitment, and our students for their help with data collection and preparation.

Financial support. The HAMLETT study is funded by ZonMW in the Netherlands (grant number 80-84800-98-41015). The funders have no role in the study design, collection, management, analysis and interpretation of data, writing the report, or the decision to submit the report for publication.

Conflicts of interest. The authors report no potential conflicts of interest.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

1Department of Biomedical Sciences of Cells and Systems, and Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2Department of Early Psychosis, Amsterdam UMC, Academic Medical Center, Amsterdam, The Netherlands; 3Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 4Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands; 5Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MheNS), Maastricht University Medical Centre, Maastricht, The Netherlands; 6King’s College London, King’s Health Partners Department of Psychiatry Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK; 7Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, location VUMc, Amsterdam, The Netherlands; 8Department of Clinical, Neuror and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit, Amsterdam, The Netherlands; 9Centre of Economic Evaluation & Machine Learning, Trimbos Institute (Netherlands Institute of Mental Health), Utrecht, The Netherlands; 10Department of Research, Arkin Mental Health Care, Amsterdam, The Netherlands; 11Antes Center for Mental Health Care, Rotterdam, The Netherlands; 12Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands; 13Department of Psychiatry, Erasmus MC, Rotterdam, The Netherlands; 14NHL/Stenden, University of Applied Sciences, Leeuwarden, The Netherlands; 15Kien VIP Mental Health Care Services, Leeuwarden, The Netherlands; 16Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA; 17Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Center, Maastricht, The Netherlands; 18Institute for Mental Health Care Eindhoven (GGZE), Eindhoven, The Netherlands; 19Janssen-Cilag B.V., Breda, the Netherlands; 20Mondriaan Mental Health Care, Heerlen, The Netherlands; 21Dimec Institute for Mental Health, Deventer, Zwolle, The Netherlands; 22Early Intervention Team, GGZ Centraal, Amersfoort, The Netherlands; 23Julius, Mental Health Institute, Dordrecht, The Netherlands; 24Reiner van Arkel Institute for Mental Health Care, ’S Hertogenbosch, The Netherlands; 25Program for Psychosis & Severe Mental Illness, Pro Persona Mental Health, Wolfheze, The Netherlands; 26Lentis Research, Lentis Psychiatric Institute, Groningen, The Netherlands; 27Center for Youth with Psychosis, Mediant ABC Twente, Enschede, The Netherlands; 28Early Psychosis Team, GGNNet, Apeldoorn, The Netherlands; 29Department of Psychotic Disorders, GGZ-Drenthe, Assen, The Netherlands; 30Department of Clinical and Developmental Neuropsychology, Faculty BSS, University of Groningen, Groningen, The Netherlands; 31Department ABC Early Psychosis, Altrecht Psychiatric Institute, Utrecht, The Netherlands; 32GGZ Delfland, Delfland Institute for Mental Health Care, Delft, The Netherlands; 33Community Mental Health, Mental Health Service Noord-Holland Noord, Alkmaar, The Netherlands and 34Early Intervention Psychosis Team, GGZ incGeest Specialized Mental Health Care, Hoofddorp, The Netherlands.

References


